Continued 20 Short Title: PM-5: Evaluation of LVEF PM-5: AMI: Evaluation of LVEF Measure Description: Percentage of patients, age 18 y, hospitalized with AMI, with documentation in the hospital record that LVEF is evaluated during hospitalization or is planned for after discharge. Numerator Patients with AMI with documentation in the hospital record that LVEF assessment, which can be either qualitative or quantitative, is done during the hospitalization or is planned for after discharge Denominator All patients with AMI Denominator Exclusions Patients age <18 y Patients who leave against medical advice Patients who die during hospitalization Patients who are on comfort care measures only or hospice Patients who are transferred to another hospital for inpatient acute care Denominator Exceptions None Measurement Period Encounter Sources of Data Medical record or other database (eg, administrative, clinical, registry) Attribution Measure reportable at the facility or provider level Care Setting Inpatient Rationale LVEF is important from a therapeutic and prognostic standpoint for patients with acute AMI for many reasons: Patients with reduced LVEF may benefit from specific medical therapies, such as inhibitors of the renin-angiotensin-aldosterone system. The presence of LVSD may help inform and guide the invasive strategy and revascularization modality (eg, further risk stratification in patients with NSTEMI, use of percutaneous circulatory assist devices during percutaneous coronary interventions, choice of surgical revascularization). LVEF is one of the strongest predictors of long-term survival following AMI. LVEF measurement during hospitalization provides a baseline and dictates outpatient reassessment a few weeks later in patients with initially depressed post-MI LVEF. This will help guide the need for device therapy. LV function can be assessed by a variety of modalities (eg, contrast ventriculography, echocardiography, CT angiography). However, a transthoracic echocardiogram is most useful. 